Researchers at ETH Zürich have developed magnetic microbots that travel through blood vessels to expedite the dissolution of life-threatening clots, according to research announced by the university on November 9.
In preclinical trials, these tiny robots reduced clot-dissolving time by 90% compared to traditional medication, potentially transforming the management of acute cardiovascular blockages.
Clinical Mechanisms of Targeted Thrombolysis
Blood clots, or thrombi, often create “branched pipe” scenarios within the circulatory system. When a vessel is occluded, blood flow—and the subsequent delivery of thrombolytic (clot-dissolving) drugs—is diverted to easier, unobstructed routes. This leaves the site of the blockage starved of medication, as explained by Simone Schürle, professor of medical microsystems at ETH Zürich, to Live Science.
By utilizing external rotating magnetic fields, these bullet-shaped microbots—constructed with an iron oxide nanoparticle backbone and a hydrogel sheath—somersault through the vasculature. This motion generates fluid vortices that physically transport medication directly into the occluded zone.
Microbots Deliver Clot-Dissolving Medicine Faster and Safely
- Targeted Delivery: The microbots act as tiny, magnetically controlled couriers that force clot-dissolving medicine into blocked areas where blood flow would otherwise naturally bypass.
- Enhanced Speed: In both silicon models and live animal testing, the integration of these robots allowed existing drugs to dissolve clots approximately 10 times faster than when the drugs were administered alone.
- Material Safety: Preliminary studies in mice indicate that the iron oxide and hydrogel materials used to build the robots are biodegradable and safely break down within the body over several weeks.
Preclinical Testing in Porcine Models
The research team successfully demonstrated the efficacy of these robots in live pigs, specifically targeting clots induced in the animals’ kidneys. By introducing the micro-robots alongside state-of-the-art thrombolytic therapy, researchers observed significantly improved reperfusion—the restoration of blood flow—to the affected tissue, according to Live Science.
The primary research team at ETH Zürich emphasizes the use of rotating magnetic fields to induce a “tumbling” motion that avoids particle clumping, a common challenge in micro-scale robotics.
“When we introduced our micro-robots with a conventional, state-of-the-art drug, we could reperfuse [restore blood flow to] a much larger area than if only the drug was there,” Schürle said.
Researchers Focus on Safety Studies and Manufacturing Scale
Although the results are promising, the technology remains in the early stages of development. The recent porcine studies did not evaluate the long-term metabolic breakdown of the robots or post-procedure health outcomes for the animals.
The team is now shifting focus toward rigorous longitudinal safety studies, which are mandatory before any human clinical trials can be considered by regulatory bodies. Schürle has filed a patent for a droplet-based microfluidic production technique, which is designed to be a high-throughput, cost-effective method for manufacturing the devices at scale.
Experimental Status Requires Standard Medical Care for Acute Symptoms
This technology is currently strictly experimental and not available for clinical use. Patients currently prescribed thrombolytic medications for conditions like deep vein thrombosis (DVT) or pulmonary embolism should continue their standard care as directed by their physician.
Anyone experiencing sudden symptoms of a cardiovascular event—such as crushing chest pain, sudden numbness, or difficulty speaking—must seek emergency medical services immediately, as these remain the only validated methods for managing acute blockages.
| Metric | Traditional Thrombolytics | Microbot-Assisted Delivery |
|---|---|---|
| Targeting Mechanism | Systemic/Flow-dependent | Magnetic/Active Navigation |
| Clot Dissolution Speed | Baseline | ~10x Faster (Preclinical) |
| Manufacturing | Standard Pharmaceutical | Droplet-based Microfluidics |
The research team acknowledges that further investigation into the interaction between the robots and the human vascular environment is required. As the technology moves toward larger animal models, the focus will be on ensuring that the devices do not trigger an immune response or cause secondary embolisms as they travel through the arterial system.